부인과암 치료제 시장 규모 : 유형별, 용도별, 치료법별, 지역별 및 예측별

Global Gynecological Cancers Therapeutics Market Size and Forecast

Global Gynecological Cancers Therapeutics Market was valued at USD 7.8 Billion in 2025 and is estimated to reach USD 12.5 Billion by 2033, growing at a CAGR of 6.5% from 2027 to 2033.

The gynecological cancers therapeutics sector is experiencing substantial growth, driven by advancements in treatment options and rising awareness of women's health issues. In the United States, the Centers for Disease Control and Prevention (CDC) has emphasized the critical importance of care from gynecologic oncologists for ovarian cancer patients, highlighting that specialized treatment significantly improves patient survival and outcomes. This focus on expert-led interventions underscores the increasing demand for innovative therapies that can effectively manage gynecological cancers while reducing treatment-related complications.

Global Gynecological Cancers Therapeutics Market Definition

The pharmaceutical and healthcare industry focused on the development, production, and commercialization of drugs and treatment approaches used to manage cancers affecting the female reproductive system. These cancers include Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Vaginal Cancer, and Vulvar Cancer. The market includes a range of treatment modalities such as chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and radiation therapy aimed at eliminating cancer cells, slowing tumor progression, improving survival outcomes, and enhancing patient quality of life. It also encompasses research and development activities, clinical trials, regulatory approvals, and the distribution of oncology therapeutics used in hospitals, cancer treatment centers, and specialty clinics worldwide.

Global Gynecological Cancers Therapeutics Market Overview

The worldwide industry involved in the research, development, manufacturing, and commercialization of therapies used to treat cancers of the female reproductive system, including Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Vaginal Cancer, and Vulvar Cancer. The market encompasses various treatment modalities such as chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and radiation therapy that aim to control tumor growth, eliminate cancer cells, and improve patient survival and quality of life. It also includes activities related to oncology drug discovery, clinical development, regulatory approvals, and the global distribution of these therapeutics across hospitals, specialty cancer centers, and healthcare institutions. Growth of this market is supported by increasing cancer incidence, advancements in precision medicine, expanding oncology research, and improved access to cancer treatment worldwide.

Global Gynecological Cancers Therapeutics Market: Segmentation Analysis

The Global Gynecological Cancers Therapeutics Market is segmented based on Type, Application, Therapeutic and Geography.

Global Gynecological Cancers Therapeutics Market By Type

Ovarian Cancer

Cervical Cancer

Uterine (Endometrial) Cancer

Vaginal Cancer

Vulvar Cancer

Ovarian cancer therapeutics constitute the largest segment due to high prevalence and aggressive nature of the disease. Cervical cancer treatments follow closely, supported by increasing HPV vaccination and screening efforts.

Global Gynecological Cancers Therapeutics Market By Application

Hospitals

Specialty Oncology Clinics

Research Institutes

Ambulatory Surgical Centers

Others

Hospitals represent the largest segment due to the availability of advanced diagnostic facilities, multidisciplinary oncology teams, and access to complex therapies including chemotherapy and immunotherapy. Specialty oncology clinics focus on dedicated cancer care, offering targeted treatments, follow-up services, and personalized therapy plans for patients.

Global Gynecological Cancers Therapeutics Market By Therapeutic Type

Chemotherapy

Targeted Therapy

Immunotherapy

Hormone Therapy

Radiation Therapy

Surgery

Others

Chemotherapy remains widely used but targeted therapies and immunotherapies are rapidly gaining share due to their specificity and improved outcomes. Among administration routes, oral therapies are preferred for convenience and patient compliance, though intravenous treatments remain common in hospitals.

Global Gynecological Cancers Therapeutics Market By Geography

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Based on Geography, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America leads the gynecological cancers therapeutics market, driven by advanced healthcare infrastructure, high healthcare spending, and strong research capabilities. Europe holds a significant market share, supported by favorable regulatory frameworks and increasing emphasis on personalized medicine. Asia Pacific is the fastest growing region with expanding healthcare infrastructure, rising awareness, and increasing prevalence of gynecologic cancers.

Key Players

The Global Gynecological Cancers Therapeutics Market is highly fragmented with the presence of a large number of players. Some of the major companies include AstraZeneca, GlaxoSmithKline plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA AGE GROUPS

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET OVERVIEW
• 3.2 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS, BY TYPE
• 3.8 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.9 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET ATTRACTIVENESS ANALYSIS, BY THERAPEUTIC TYPE
• 3.10 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET, BY TYPE (USD BILLION)
• 3.12 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET, BY APPLICATION (USD BILLION)
• 3.13 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET, BY THERAPEUTIC TYPE (USD BILLION)
• 3.14 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET, BY GEOGRAPHY (USD BILLION)
• 3.15 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET EVOLUTION
• 4.2 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE GENDERS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TYPE
• 5.3 OVARIAN CANCER
• 5.4 CERVICAL CANCER
• 5.5 UTERINE (ENDOMETRIAL) CANCER
• 5.6 VAGINAL CANCER
• 5.7 VULVAR CANCER

6 MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
• 6.3 HOSPITALS
• 6.4 SPECIALTY ONCOLOGY CLINICS
• 6.5 RESEARCH INSTITUTES
• 6.6 AMBULATORY SURGICAL CENTERS
• 6.7 OTHERS

7 MARKET, BY THERAPEUTIC TYPE

• 7.1 OVERVIEW
• 7.2 GLOBAL GYNECOLOGICAL CANCERS THERAPEUTICS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY THERAPEUTIC TYPE
• 7.3 CHEMOTHERAPY
• 7.4 TARGETED THERAPY
• 7.5 IMMUNOTHERAPY
• 7.6 HORMONE THERAPY
• 7.7 RADIATION THERAPY
• 7.8 SURGERY
• 7.9 OTHERS

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 KEY DEVELOPMENT STRATEGIES
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 ACE MATRIX
  • 9.4.1 ACTIVE
  • 9.4.2 CUTTING EDGE
  • 9.4.3 EMERGING
  • 9.4.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 ASTRAZENECA
• 10.3 GLAXOSMITHKLINE PLC
• 10.4 BRISTOL-MYERS SQUIBB COMPANY
• 10.5 F. HOFFMANN-LA ROCHE LTD
• 10.6 MERCK & CO., INC.